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Introduction
Influenza constitutes a serious problem for healthcare 
and social services worldwide, owing to its pattern of 
recurrent epidemics and pandemics and the severity of 
its complications in some categories of subjects at risk, 
such as the elderly, those with pulmonary, cardiovascu-
lar, kidney, liver, hematological and metabolic disor-
ders, and immunocompromised patients [1]. Indeed, flu 
vaccination is offered free of charge to these categories 
of subjects in all developed countries.
Each year, an average of 5-20% of the population catch-
es influenza and more than 200,000 people are hospital-
ized for complications related to seasonal influenza in 
the United States [2]. Sullivan et al. estimated 314,000 
hospitalizations per year due to flu syndrome in the 
USA [3]. In the 30 years between 1976 and 2006, esti-
mates of influenza-associated deaths ranged from a min-
imum of about 3,000 to a maximum of about 49,000 [2]. 
During the typical winter influenza epidemics of recent 
years, the average annual number of deaths attributable 
to influenza (all causes, all age-classes) is 12,000 in Eng-
land and Wales [4]. Some categories of subjects, such as 
the elderly, young children, pregnant women and people 
with certain medical conditions (immunocompromised 
individuals, those with chronic diseases, etc.), have an 
increased risk of developing severe complications as a 
result of influenza infection. Furthermore, uremic pa-
tients are especially vulnerable to infections [5], and 
it is generally recommended that patients with chronic 
renal insufficiency should be vaccinated yearly against 
influenza [6]. In patients on hemodialysis (HD), the in-
fluenza vaccination response has been considered sub-
optimal [7].
About 90% of excess mortality due to influenza and 
about 50% of excess hospitalizations occur among the 
elderly [8]. Moreover, as underlined by the US Cent-
ers for Disease Control (CDC), the complications of 
influenza more often affect persons over 64 years of 
age, especially those aged more than 75 years, as well 
as children and people of all ages with recognized risk 
conditions [9].
It is acknowledged that the only really effective means 
of combating influenza and its possible complications 
is vaccination [10]. However, the efficacy of a vaccine 
depends on the concordance between the strains used for 
immunization and the virus circulating among popula-
tions (matching). Vaccine efficacy is strongly influenced 
by the conditions of immune system and the age of re-
cipients. Many studies support the hypothesis that influ-
enza vaccination significantly reduces the risk of severe 
complications, e.g. hospitalizations for pneumonia and 
death among the elderly living in communities [11-13]. 
In subjects over 64 years of age, vaccination against in-
fluenza seems to reduce hospitalizations by 50-60% and 
mortality by up to 80% [9].
The need for ever more immunogenic and efficacious 
influenza vaccines, especially for subjects at risk, has 
prompted the development of adjuvated vaccines. In 
order to enhance the immune response to influenza vac-
cines, several adjuvants have been proposed (e.g. alum 
salts, MF-59®, liposomes, virosomes, etc.) [14, 15]. 
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Summary
Influenza constitutes a serious problem for healthcare and social 
services worldwide, owing to its pattern and the severity of its 
complications in some categories of subjects at risk, such as the 
elderly and immunocompromised individuals. The only really 
effective means of combating influenza is vaccination. The elderly 
and immunocompromised subjects are refractory or low respond-
ers to vaccination. The need for ever more immunogenic and 
efficacious influenza vaccines, especially for subjects at risk, has 
prompted the development of adjuvated vaccines. With a view to 
enhancing the immune response in the elderly and in subjects at 
risk, the possibility of co-administering immunostimulants as Thy-
mosin α-1 (Tα1) with influenza vaccines has been investigated. 
Tα1 is a biologically active peptide made up of 28 amino acids 
that can enhance T-cells, dendritic cell and antibody responses, 
modulate cytokines and chemokines production. Several studies 
were conducted and showed that Tα1 ameliorate the performance 
of influenza vaccination in elderly and subjects at risk.
Although further studies on co-adjuvants are necessary, the future 
prospects of producing ever more efficacious influenza vaccines 
appear very promising.
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Adjuvants are agents which, when incorporated into 
vaccines, enhance the immunogenicity of their anti-
gens by activating and/or prolonging their stimulatory 
effect.
The reasons for developing adjuvated influenza vac-
cines are:
• to enhance the immune response in subjects in whom 
the efficiency of cell-mediated and humoral immu-
nity is reduced, such as elderly or immunocompro-
mised persons;
• to produce a powerful vaccine for subjects at risk, 
such as those with chronic disorders;
• to improve the immunogenicity of highly purified or 
recombinant antigens;
• to increase antigen delivery systems for the uptake of 
antigens by the mucosa;
• to obtain vaccines able to enhance cross-reactivity 
versus a broad spectrum of strains similar to those 
contained in the vaccine formulation;
• to reduce the amount of antigens per dose and the 
number of doses necessary in unprimed children un-
der 9 years;
• to provide cover for the entire influenza season;
• to develop pre-pandemic and pandemic vaccines.
With a view to enhancing the immune response in the 
elderly and in subjects at risk, the possibility of co-ad-
ministering immunostimulants with influenza vaccines 
has been investigated. In this perspective, the potential 
of Thymosin α-1 (Tα1) (Zadaxin™) to increase the 
immune response to influenza vaccination has been 
studied.
Thymosin α-1 (Zadaxin™)
Thymosins are biologically active substances pro-
duced by the human organism. Tα1 is a biologically 
active peptide made up of 28 amino acids. In 1966, 
Goldstein et al. first isolated and described a lym-
phocytopoietic factor obtained from calf thymus [16]; 
they subsequently sequenced Tα1 [17] and studied its 
activity on the immune, endocrine and central nerv-
ous systems [18].
Thymosin is a protein produced naturally by the thymus 
and in many other cells of the organism. It acts on the 
maturation of the immune system and the production of 
T cells and exerts a regulatory effect on many essential 
biological processes in order to ensure proper function-
ing of the immune system. Indeed, the main biological 
properties of thymosin include enhancement of T-cell-
dependent specific antibody production, helper T-cell 
activity and secondary T-cell-dependent IgG, IgM, and 
IgA antibody responses [19, 20].
Zadaxin™ was provided by Sigma-Tau SpA. Zadaxin™ 
is approved in Italy as an adjuvant for influenza vaccine 
in immunocompromised subjects. Zadaxin™ contains 
Tα1, a 28 amino acid peptide acetylated at its amino 
terminus. Chemically synthesized Tα1 is identical in 
amino acid sequence to the Tα1 isolated from Thymosin 
fraction-5, an extract from the thymus gland.
Mechanism of action
Although numerous studies have aimed at clarifying 
the immunoregulatory activity of Tα1, the mecha-
nisms through which this activity is carried out have 
not yet been completely explained. Amhed et al. [21] 
found that Tα1 enhanced the efficiency of T lym-
phocyte maturation. Peng et al. [22] demonstrated 
that Tα1 stimulated the differentiation of stem cells to 
CD4+ and CD8+ lymphocytes. Yao et al. [23] showed 
the importance of Tα1 in the balancing of CD3, CD4+ 
and CD8+ lymphocytes and peripheral monocytes 
(PBMCs).
Rustgi [24] hypothesized that Tα1 exerts an antiviral 
action through the direct stimulation of Natural Killers 
(NK) and cytotoxic T lymphocytes (CD8+).
Leichtling et al. [25] noted that Tα1 induced an increase 
in the sensitivity of specific cellular receptors for inter-
leukin 2 (IL-2).
Other direct effects on the effector cells of the immune 
system have been observed. These concern: the direct 
inhibition of viral replication [26] and an action that 
renders viral antigens in infected cells more evident, 
therefore facilitating attack by the cells of the immune 
system [27].
An immunoregulatory action of Tα1 has also been ob-
served. Garaci et al. [28] hypothesized that Tα1 might di-
rectly stimulate the genes of the cytokines, of the cells of 
the major histocompatibility complex I (MHCI) and of the 
major histocompatibility complex II (MHCII) or unknown 
genes that might act as immune system regulators.
Naylor et al. [29] demonstrated that both T lymphocytes 
and monocytes exposed to Tα1 display greater sensitiv-
ity for the genes coding for the proteins of the major 
histocompatibility complex, for the co-stimulatory mol-
ecules, for chemokines and for cytokines. Moreover, 
Tα1 also enhances the sensitivity of the related cellular 
receptors.
On investigating the effect of Tα1 on the modalities 
of intracellular signaling, Sungarian et al. [30] ob-
served a stimulatory effect on the protein kinases that 
activate the mitogens (MAPK); previously, Zhang 
et al. [31] had demonstrated the activation of I (Ka-
ppa) B kinase (IKK), which represents a signal for the 
receptor-associated factor 6 (TRAF6). Moreover, Tα1 
is thought to stimulate the production of IL-6, IL-10 
and IL-12. In addition, Romani et al. [32] showed that 
Tα1 exerted sensitizing action on the dendritic cells 
(DC) through the signal on the Toll-like receptor 9 
(TLR9) and on factor 88 by means of myeloid dif-
ferentiation (MyD88). Again with regard to the matu-
ration and differentiation of the DC, Yao et al. [23] 
underlined the activation by Tα1 of the p38 MAPK 
and NF-κB pathways.
Activation of the plasmacytoid dendritic cells (pDC) 
leads to the activation of interferon regulatory factor 
7 and promotion of the IFN-α/IFNγ activation path-
way [32]. Moreover, the activation of indoleamine 2,3-
dioxygenase (IDO) can improve tolerance to transplan-
tation and reduce allergic inflammation [33].
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Qin et al. [34] recently found that Tα1 inhibits the pro-
liferation of HepG2 cells, and that this inhibition may 
be associated to the protein kinase B signal (AKT). 
Finally, Bonifazi et al. [35] have hypothesized that 
Tα1 is a regulator of regulators. Specifically, Tα1 is 
thought to occupy a central and bivalent position of 
stimulation and regulation. By this token, it would 
stimulate the DC through the TLRs, inducing the pro-
duction of cytokines. Moreover, through the TLRs, 
Tα1 would activate Th17 cells, which would in turn 
induce a negative effect on allergies and inflamma-
tory syndromes.
In synthesis, Tα1 acts on the immune system in the fol-
lowing ways:
• it stimulates stem cell differentiation;
• it increases the number of T cells that destroy virus-
es, including CD4, CD8 and Natural Killers derived 
from the stem cells;
• it slows down the apoptosis of the T cells, which are 
of primary importance in the immune response;
• it increases the number of helper cells (Th1 cells), 
which combat chronic viral infection;
• it increases the production of cytokines, which act to 
raise the number of T cells in the process of the im-
mune response. In particular, it increases the produc-
tion of interleukin 2 and interferon gamma;
• it reduces the production of interleukin 4 and inter-
leukin 10, which exert an unfavorable effect on re-
sistance to chronic viral infections.
Tα1 acts directly on virus-infected cells in the following 
ways:
• it increases the number of surface protein marker 
molecules (MHC I), which are responsible for iden-
tifying and eliminating from the organism foreign 
bodies, such as viruses;
• it slows down viral replication.
Utility of Tα1 in potentiating the influenza 
vaccine response
Several studies were conducted and showed that Tα1 
can improve response in populations of individuals who 
are refractory or low responders to vaccination.
Influenza vaccination is strongly suggested for the eld-
erly because in this category of subjects there is an in-
creased risk of developing severe complications as a re-
sult of influenza infection. Nevertheless, the degree of 
protection that can be achieved is sometimes reduced as 
a result of immunosenescence [36]. This problem is also 
linked to the ageing of the thymus, which results in a 
lower production of its hormones and a reduction in the 
availability of T lymphocytes [37].
In 2005, Jefferson et al. [38] published the results of a 
meta-analysis which indicated a mean efficacy of influ-
enza vaccination of 23% in the elderly. In other stud-
ies, vaccine efficacy among elderly subjects has been 
estimated as 57.11% (1999-2000 season) and 45.74% 
(2000-2001 season) [39, 40].
In 2005, Goodwin et al. published a paper concerning 
31 studies of the immune response to influenza vacci-
nation in elderly subjects; the response seen in elderly 
subjects (> 65 years) proved to be between 4 and 1.69 
times lower than in the young [41].
Several strategies to improve the response to influenza 
vaccination in the elderly have been examined. Some are 
based on conjugation of the vaccine with proteins such 
as diphtheria toxoid [42]; others involve increasing the 
quantity of antigen or the number of doses [43], while 
others again utilize new adjuvants, such as liposomes or 
oil emulsions in water [44-46].
Even for subjects at risk as immunocompromised sub-
jects, the vaccination is strongly indicated.
In this perspective since the yearly 80s, Tα1 has been 
studied with regard to its potential ability to increase the 
immune response to vaccination.
Tα1 has been seen to enhance vaccine responses in both 
animal experiments and human trials [47-49]. These 
experiments have suggested that the co-administration 
of Tα1 and vaccine can potentiate antibody produc-
tion [47, 48].
Studies conducted on a human model [49, 50] have 
shown that the addition of thymosin to influenza vaccine 
enhances the production of antibodies. In a study of this 
kind carried out by Gravestein et al. [51] high levels of 
antibody production were achieved in 9 elderly subjects 
who had not responded to vaccination a year earlier. 
The same author subsequently conducted a double-blind 
study on 90 elderly subjects vaccinated against influenza 
with/without simultaneous administration of thymosin. 
The results confirmed the efficacy of thymosin; indeed, 
a response to vaccination was recorded in 69% of the 
subjects who had received thymosin, as against 52% of 
those who had received the vaccine alone. The differ-
ence between these two percentages proved statistically 
significant (p = 0.023) [52].
Similarly, in a study conducted by McConnell on 330 
elderly subjects, the administration of thymosin after ad-
ministration of the vaccine yielded significant improve-
ments in the immune response towards all three influ-
enza virus strains contained in the vaccine [53].
More recently, Tuthill et al. [54] utilized an animal 
model to investigate different dosage regimes imple-
mented at different times in relation to the administra-
tion of an influenza vaccine adjuvated or not adjuvated 
with MF59® in 23 groups of mice. On the basis of their 
results, the authors concluded that the best strategy was 
to administer Tα1 one week before and on the same day 
as the influenza vaccine. Moreover, these authors also 
studied the potential of Tα1 in 5 groups of 4 ferrets (with 
regard to influenza, this animal model is the closest to 
man) and observed that the best results were obtained by 
administering Tα1 at a dose of 6.4 mg one week before 
and on the same day as the influenza vaccine.
Even in immunocompromised subjects, such as those on 
hemodialysis, the administration of Tα1 can help to im-
prove influenza vaccine responses [55]. The study was 
conducted by Shen et al. on 97 hemodialysis patients 
vaccinated with a monovalent preparation (A/H1N1/
Taiwan/1/86). The results showed a significant improve-
ment in immune response (p < 0.002) in the group of 
subjects treated with thymosin. The same author has 
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studied Tα1 in co-administration with anti-hepatitis B 
vaccine. The subjects treated with Tα1 showed a better 
response to the vaccine than those who had received the 
vaccine alone [56, 57].
Conclusions
Forty years after the first description and characteriza-
tion of Tα1 by Goldstein [16, 17], it is used worldwide 
with many medical applications. Nowadays, Tα1 has 
shown a variety of effects on cells and pathways of the 
immune system, its central role is stimulating T lym-
phocytes. Furthermore Tα1 has an important capacity 
of immunoregulatory action. Tα1 also acts directly on 
virus-infected cells increasing the number of surface 
protein marker molecules and slowing down viral rep-
lication. Finally, Bonifazi et al. [35] have hypothesized 
that Tα1 is a regulator of regulators.
The goals of influenza vaccination are to elicit a strong 
and, if possible, broad-spectrum immune response in 
all the subjects also in those individuals who are refrac-
tory or low responders to vaccination. Particularly, it is 
important that the subjects, whose immune systems are 
impaired to some degree by concomitant diseases and 
who are at greater risk of developing severe forms of the 
influenza disease, are protected. Undoubtedly, adjuvated 
vaccines offer good prospects. However, further oppor-
tunities could be provided by combining immunomodu-
lators with influenza vaccines. In this perspective, the 
results of the studies on Tα1 were encouraging. Indeed, 
Tα1 can potentiate the production of specific antibodies 
that are dependent on the function of the T lymphocytes. 
Therefore, Tα1 could contribute to reduce the amount 
of antigen per dose leading to have cheaper and more 
amount of vaccine doses particularly in emergency mas-
sive vaccination programs. Tα1 could ameliorate the 
performance of vaccination in particular clinical set-
tings.
The findings, obtained in the studies where Tα1 was used 
as co-adjuvant to vaccination, allow to suppose similar 
results for other vaccines, especially those for the pre-
vention of infectious diseases caused by pathogens with 
a wide variety or variability of antigenic phenotypes. 
Furthermore Tα1 could be used when it is necessary to 
have a quick immune response such as in traveling and 
case of pandemia.
Finally the immunoregulatory and anti-inflammatory 
actions of Tα1 could be useful to reduce severe adverse 
events in vaccination (e.g. severe allergic reaction, Guil-
lan-Barré syndrome).
Furthermore, immunomodulators could be studied for 
use in intranasal influenza vaccines.
In conclusion, although further studies on co-adjuvants 
are necessary, the future prospects of producing ever more 
efficacious influenza vaccines appear very promising.
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